Lamivir HBV 100mg (Lamivudine)

Lamivir HBV 100 mg – Product Description

Brand Name: Lamivir HBV 100 mg
Active Ingredient: Lamivudine 100 mg
Drug Class: Nucleoside Reverse Transcriptase Inhibitor (NRTI), Antiviral
Manufactured By: Cipla Ltd.
Packing Details: Available in bottle packs of 30 tablets.

Description:

Lamivir HBV 100 mg contains Lamivudine, an antiviral medication used to treat chronic hepatitis B virus (HBV) infection. It works by inhibiting the HBV reverse transcriptase enzyme, which prevents the virus from multiplying and reduces viral load. This helps slow down liver damage, fibrosis, and cirrhosis while improving liver function.

Uses:

Lamivir HBV 100 mg is prescribed for:

✔ Chronic Hepatitis B Virus (HBV) Infection
✔ Helps Reduce HBV Viral Load & Prevents Liver Damage
✔ Slows Progression of Liver Disease (Cirrhosis & Fibrosis Prevention)

Dosage & Administration:

• For Adults & Adolescents (≥16 years): 100 mg once daily

• Route of Administration: Oral – Can be taken with or without food.

• Missed Dose: Take as soon as remembered unless it is close to the next dose—do not double dose.

Side Effects:

Common side effects may include:
✔ Nausea, vomiting
✔ Fatigue, dizziness
✔ Headache, diarrhea
✔ Abdominal pain

Serious side effects (seek medical attention immediately):
⚠ Lactic acidosis: Unusual tiredness, muscle pain, irregular heartbeat
⚠ Liver problems: Yellowing of skin/eyes, dark urine
⚠ Immune reconstitution syndrome: Temporary worsening of infections

Precautions & Warnings:

⚠ Not a cure for Hepatitis B – Controls infection but does not eliminate it.
⚠ Do not stop medication suddenly – Can cause HBV flare-ups.
⚠ Use with caution in patients with kidney disease.
⚠ Pregnancy & Breastfeeding: Consult a doctor before use.

Storage Instructions:

✔ Store at room temperature (below 30°C), away from moisture and direct sunlight.
✔ Keep out of reach of children.

Disclaimer:

This information is for educational purposes only. Always consult a doctor before using Lamivir HBV 100 mg (Lamivudine).